Skip to content

R&D at other companies

Eli Lilly logo
Eli LillyLLY
$3.51B+28.4%
Rogers Corporation logo
Rogers CorporationROG
$6.7M-5.6%
TG Therapeutics logo
TG TherapeuticsTGTX
$48.4M+4.4%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$76.87M-1.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$33.99M-17.5%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$58.85M-4.5%

Segments

By segment

See full
Reportable Segment$172.8M-3.2%

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.89B+72.3%
Enterprise value$35.07B+57.0%
P/E22.5×+10.4×
P/S3.2×+1.4×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's R&D?
Biogen (BIIB) reported R&D of $539M in Q1 2026.
How has Biogen's R&D changed year-over-year?
Biogen's R&D increased by 24.2% year-over-year, from $434.1M to $539M.
What is the long-term trend for Biogen's R&D?
Over 4 years (2021 to 2025), Biogen's R&D has grown at a -8.2% compound annual growth rate (CAGR), from $2.5B to $1.78B.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.